Therefore, we used databases or webservers such as TCGA, Tumor Immune Estimation Resource 2.0 (TIMER2.0), GEO, and Gene Expression Profiling Interactive Analysis 2 (GEPIA2) to conduct pan-cancer analysis of KRT17 and explore the potential molecular mechanisms by which it relates to the occurrence, development, and clinical prognosis of different cancer types. This evidence concerns the gene KRT17 and neoplasm.